Plus Therapeutics (PSTV) Other Accumulated Expenses (2011 - 2026)
Plus Therapeutics (PSTV) reported Other Accumulated Expenses of $146000.0 for Q1 2026, down 8.18% quarter-over-quarter from $159000.0 in Q4 2025.
Plus Therapeutics (PSTV) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 13 years of Other Accumulated Expenses data on file, last reported at $146000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $146000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $146000.0 (changed N/A YoY), and the FY2025 annual result was $159000.0, changed N/A from the prior year.
- Other Accumulated Expenses slipped to $146000.0 in Q1 2026 per PSTV's latest filing, from $159000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $159000.0 in Q4 2025 and troughed at $146000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146,000.00 |
| Dec 31, 2025 | 159,000.00 |
| Dec 31, 2021 | 122,000.00 |
| Dec 31, 2020 | 23,000.00 |
| Dec 31, 2019 | 791,000.00 |
| Dec 31, 2018 | 201,000.00 |
| Dec 31, 2017 | 1.60 Mn |
| Dec 31, 2016 | 336,000.00 |
| Dec 31, 2015 | 2.02 Mn |
| Dec 31, 2014 | 2.01 Mn |
| Dec 31, 2013 | 2.17 Mn |
| Dec 31, 2012 | 2.07 Mn |
| Dec 31, 2011 | 1.57 Mn |